FDA proxies don't coincide with better disease outcomes: Yale study

Yale and Emory researchers question the effectiveness of using FDA drug proxies in the approval process, finding weak associations with disease outcomes.

Related Keywords

United States ,American ,Joseph Ross ,Yale School Of Medicine ,Journal Of The American Medical Association ,Emory University ,New Haven ,Yale School ,Atlanta Based Emory University ,American Medical Association ,